First-line systemic therapy for metastatic castration-sensitive prostate cancer: An updated systematic review with novel findings

Ferro, Matteo; Lucarelli, Giuseppe; Crocetto, Felice; Dolce, Pasquale; Verde, Antonio; Civita, Evelina La; Zappavigna, Silvia; Cobelli, Ottavio De; Lorenzo, Giuseppe Di; Facchini, Gaetano; Scafuri, Luca; Onofrio, Livia; Porreca, Angelo; Busetto, Gian Maria; Sonpavde, Guru; Caraglia, Michele; Klain, Michele; Terracciano, Daniela; Placido, Sabino De; Buonerba, Carlo

doi:10.1016/j.critrevonc.2020.103198

Cited by 42 publications

(33 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Prostate cancer (PCa) is the second most common neoplasm in men and the fifth leading cause of death worldwide [1]. Despite recent advancements in the diagnosis and treatment of this disease, the incidence of PCa is rising and the clinical outcomes of patients with metastatic castration-resistant prostate cancer (mCRPC) are still poor [2,3]. Excluding advanced age and African American ancestries, the only currently identified risk factor for the development of PCa is a positive family history.…”

mentioning

confidence: 99%

BRCA Germline Mutations in Prostate Cancer: The Future Is Tailored

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 99%

BRCA Germline Mutations in Prostate Cancer: The Future Is Tailored

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

“…The CTC counts obtained with CellCollector could also be tested in metastatic castration-sensitive prostate cancer patients (mCSPC) as biomarkers for evaluation of the treatment with androgen-receptor-axis-targeted (ARAT) therapy compared with docetaxel to improve the outcome in mCSPC patients [ 39 , 40 ].…”

Section: Discussionmentioning

confidence: 99%

Association of Circulating Tumor Cells with Inflammatory and Biomarkers in the Blood of Patients with Metastatic Castration-Resistant Prostate Cancer

Theil

Lindner

Białek

et al. 2021

Life

View full text Add to dashboard Cite

The identification of specific biomarkers that recognize the functional drivers of heterogeneity in prostate cancer (PCa) and personalized treatment remain challenging in systemic medicine. Liquid biopsy allows for the detection and analysis of personalized predictive biomarkers in single blood samples and specifies the current stage of cancer. The aim of our preliminary study was to investigate the association between an elevated circulating tumor cell (CTC) count and the levels of inflammatory factors (IL-6 and IL-8) and biomarkers (DKK-1, PSA, sHER2, and CD44) in patients with metastasized castration-resistant PCa (mCPRC) under chemotherapy and those with localized PCa. Such an association could be used as a component of cancer progression monitoring. We compared the sensitivity and specificity of two CTC isolation platforms. Twenty-eight patients (12 mCRPC and 16 localized PCa patients) were enrolled. Over the study period, the CTC detection rates were 84% with CellCollector® and 73.5% with CellSearch® System in mCPRC patients. The CTC counts determined by the CellSearch® System (CTC_CS) were correlated significantly with the DKK-1, sHER-2, and PSA concentrations in mCRPC patients. The CTC counts captured by CellCollector® demonstrated no significant association with the concentrations of the tested blood-based biomarkers. The CTC_CS count (AUC = 0.9 (95% CI: 0.72–1.0)) and the PSA level (AUC = 0.95 (95% CI: 0.83–1.0)) presented approximately the same sensitivity and specificity for the overall survival of mCRPC patients. For better personalized characterization, further research on CTC phenotyping and their interactions with tumor-associated blood-released factors is needed.

show abstract

“…Consequently, higher caregiver burden and lower quality of life can be observed in cases experiencing chemotherapy side effects. However, it is clear that chemotherapy improves the quality of life in eligible patients in castration resistant metastatic prostate cancer [21]. There is still controversy about the timing of chemotherapy with new generation antiandrogens in sequential treatment algorithms.…”

Section: Discussionmentioning

confidence: 99%

Evaluation of caregiver burden, and quality of life in metastatic prostate cancer patients and caregivers; Effects of clinical and socioeconomic factors

Yıldırım¹,

Poyraz²,

Erdur³

et al. 2021

Preprint

View full text Add to dashboard Cite

Purpose: To investigate the caregiver burden and quality of life (QoL) of patients with metastatic prostate cancer. The relationship between questionnaire results and medical, socioeconomic, disease and treatment related factors of the patients were evaluated. Methods: One hundred twenty one metastatic prostate cancer patients and caregivers were enrolled in this cross-sectional study. Short Form 36 (SF-36) questionnaires and Zarit caregiver burden interviews (ZCBI) were conducted with patients and their caregivers seperately. Patients’ comorbidities, presence of bone and visceral metastases, bone related events, palliative radiotherapy needs, ECOG scores, being under active chemotherapy, socioeconomic factors such as public transportation need, residential factors and caregiver related factors such as comorbidities and kinships were recorded respectively. Results: Patients’ comorbidities, ECOG score, presence and quantity of bone or visceral metastasis, bone related events, receiving palliative radiotherapy and chemotherapy, using public transportation resulted in lower SF-36 and higher ZCBI results (p < 0.001– p = 0.049). Obligation to live in rented houses were correlated with lower SF-36 physical function results (p = 0.043). Condition of the caregiver being from distant relatives resulted in a lower SF-36 score (p = 0.01 - p= 0.043). Moderate to strong negative correlation was detected between ZCBI and all SF-36 results (p < 0.001, r: -646 to -749). In ZCBI, score over 47 resulted with % 69.57 sensitivity and % 65.52 specificity (AUC = 0.671, p = 0.008). Conclusion: QoL was directly related to caregiver burden. Factors such as patient comorbidities, bone metastasis and related situations, ECOG score, presence of visceral metastasis, actively undergoing chemotherapy, low socioeconomic status and poor family support negatively affect both the quality of life of patients and caregiver burden. If a social assistance system can be implemented in which these factors can be monitored systematically, objective and cost-effective benefits related to the care of these patients and the maintenance of their quality of life can be achieved.

show abstract

First-line systemic therapy for metastatic castration-sensitive prostate cancer: An updated systematic review with novel findings

Cited by 42 publications

References 26 publications

BRCA Germline Mutations in Prostate Cancer: The Future Is Tailored

BRCA Germline Mutations in Prostate Cancer: The Future Is Tailored

Association of Circulating Tumor Cells with Inflammatory and Biomarkers in the Blood of Patients with Metastatic Castration-Resistant Prostate Cancer

Evaluation of caregiver burden, and quality of life in metastatic prostate cancer patients and caregivers; Effects of clinical and socioeconomic factors

Contact Info

Product

Resources

About